Clinical trial · Interventional
Smart Living Homes: GATEKEEPER System With Patients With Cancer and Dementia in Cyprus
SMART LIVING HOMES - WHOLE INTERVENTIONS DEMONSTRATOR FOR PEOPLE AT HEALTH AND SOCIAL RISKS
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main objective of the Project is to create a GATEKEEPER, that connects healthcare providers, businesses, entrepreneurs, elderly citizens and the communities they live in, in order to originate an open, trust-based arena for matching ideas, technologies, user needs and processes, aimed at ensuring healthier independent lives for the ageing populations. By 2022, GATEKEEPER will be embodied in an open source, European, standard-based, interoperable and secure framework available to all developers, for creating combined digital solutions for personalised early detection and interventions that (i) harness the next generation of healthcare and wellness innovations; (ii) cover the whole care continuum for elderly citizens, including primary, secondary and tertiary prevention, chronic diseases and co-morbidities; (iii) straightforwardly fit "by design" with European regulations, on data protection, consumer protection and patient protection (iv) are subjected to trustable certification processes; (iv) support value generation through the deployment of advanced business models based on the VBHC paradigm. GATEKEEPER will demonstrate its value by scaling up, during a 42-month work plan, towards the deployment of solutions that will involve ca 40.000 elderly citizens, supply and demand side (authorities, institutions, companies, associations, academies) in 8 regional communities, from 7 EU member states. Recently 3 Asian pilots have been added as a result of the Open Calls. The achievement of the overall objective is supported by the following, among others, specific objective: To execute a series of PILOTS to demonstrate the effect, benefit, value and scalability of the GATEKEEPER solutions around REFERENCE USE CASES COVERING PRIMARY, SECONDARY and TERTIARY PREVENTION, initially deployed in 8 regions of 7 European countries. The Cyprus pilot mainly focuses on the early detection of the condition worsening of cancer and dementia patients by monitoring whether the use of technology can trigger appropriate management, thereby reducing the need for higher acuity care, and even, at times, improving survival by supporting demand-driven solutions through high-quality health mobile systems.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Dementia | — | UNRESOLVED | — |
| Neoplasms | Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| GATEKEEPER | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- NO_INTERVENTION
- label
- Control group
- description
- The Control group will receive standard health care with no technical support, where the intervention groups will receive platform and device services provided to each user. In that respect, Intervention Group 1 will receive no real-time feedback, where Intervention Group 2 will unhand with real data and notifications. A control group is defined as a group of clinical trial participants who will not be provided any digital devices as part of the trial and will receive care as usual by PASYKAF and AMEN.
- type
- EXPERIMENTAL
- label
- Intervention group 1 (limited technology)
- description
- Intervention Group 1 - platform/devices (no real feedback provided (limited technology group) A limited technology group is defined as a group of clinical trial participants who receive the digital devices but not the automated interventions through the devices (prompts, messages).
- interventionNames
- Device: GATEKEEPER
- type
- EXPERIMENTAL
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion criteria (cancer patients): * Aged: Over the age of 50 years * Adequate understanding of Greek and/or English Language * Cancer diagnosis/ ICD-10: Illness classification system * Functional status/ ECOG Performance Status 0,1,2,3 * ECOG Performance Status 4 only if Phase of Illness and Prognosis permits * Phase of illness (Based on Medical Assessment and presenting prognosis/ the Patient is expected by the Health Care Team to be able to complete the 6-week study period) * Patient receiving Health Care Services from PASYKAF Exclusion criteria (cancer patients): * Aged \< 50 years * Psychiatric diagnosis Inclusion criteria (cancer patients' caregivers): * Over the age of 18 years * Adequate understanding of Greek and/or English Language * Primary caregiver of patient with cancer * Patient/ Caregiver receiving Health Care Services from PASYKAF (The primary caregiver is a family member or friend that supports a patient through cancer treatment, helps with daily activities, such as going to the doctor or preparing meals, coordinates services and care and provides emotional and spiritual support, www.cancer.gov) Exclusion criteria (cancer patients caregivers): * Aged \< 18 years * Not able to consent Inclusion criteria (healthcare professionals) * PASYKAF employed Health Care Professionals( Nurses, Psychologists, Social Workers and Physiotherapists) that provide services in all districts of Cyprus (Nicosia, Limassol, Larnaca, Paralimni, Pafos) * Adequate understanding of Greek and/or English Language
References
Publications (0)
Data not yet available